We used hyperpolarized 13C magnetic resonance spectroscopic imaging (HP 13C MRSI) and T1-MRI to assess dimethyl fumarate (DMF) response in a model of multiple sclerosis (MS). Gadolinium-enhanced T1-MRI showed blood-brain-barrier breakdown, regardless of DMF treatment. In contrast, DMF therapy prevented an increase compared to untreated MS animals in HP 13C lactate, HP 13C lactate-to-pyruvate and HP 13C lactate-to-(pyruvate/urea) ratios. HP 13C MRSI findings were further correlated to pyruvate dehydrogenase activity and pro-inflammatory macrophages. Altogether, we demonstrated that HP 13C MRSI has potential to monitor the effect of immunomodulatory therapies within the central nervous system.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords